The Pharmaceutical Research and Manufacturers of America (PhRMA), in a new report, said that America’s biopharmaceutical companies are researching 282 medicines currently in clinical trials or under review by the FDA “to help meet the unique health care needs of children and adolescents.” The reviews these medicines noting:

– 54 for cancer which, despite significant progress, is still the leading cause of death by disease among American children,

– 49 for infectious diseases, resulting in more than 164 million missed school days annually in American public schools due to the spread of infectious diseases,

– 48 for genetic disorders, including medicines for cystic fibrosis, which affects 30,000 American children and adults,

– 25 for neurologic disorders, including medicines for epilepsy, which affects more than 300,000 school children under age 14 in the United States.

The report is available here: http://bit.ly/xRAVhd

http://www.phrma.org/media/releases/nearly-300-medicines-development-meet-unique-needs-children